Compile Data Set for Download or QSAR
Report error Found 13 Enz. Inhib. hit(s) with all data for entry = 12351
TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 6.79nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 9.49nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 39.9nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697084(US20240309004, Compound VKT-511)
Affinity DataIC50: 46.5nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697083(US20240309004, Compound VKT-036)
Affinity DataIC50: 68.1nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697082(US20240309004, Compound VKT-034)
Affinity DataIC50: 80.7nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697081(US20240309004, Compound VKT-007)
Affinity DataIC50: 110nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697081(US20240309004, Compound VKT-007)
Affinity DataIC50: 152nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697085(US20240309004, Compound VKT-320)
Affinity DataIC50: 1.68E+3nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697082(US20240309004, Compound VKT-034)
Affinity DataIC50: 2.54E+3nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697083(US20240309004, Compound VKT-036)
Affinity DataIC50: 3.64E+3nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697081(US20240309004, Compound VKT-007)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetCyclin-H/Cyclin-dependent kinase 7(Human)
Virokyne Therapeutics

US Patent
LigandPNGBDBM697081(US20240309004, Compound VKT-007)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds VKT-007, VKT-034, VKT-036, and VKT-511 were tested in 10-dose IC50 duplicate mode with a 3-fold serial dilution starting at 10 μM. Con...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent